PepGen

#Neuromuscular Disease #Neurology #Rare Disease

Clinical-stage biotechnology company developing next-generation oligonucleotide therapies built on its Enhanced Delivery Oligonucleotide (EDO) platform of cell-penetrating peptides, aimed at severe neuromuscular and neurological diseases.

Company Info

Sector:Biotechnology — Genetic Medicine

Headquarters:Boston, Massachusetts, USA

Founded:2018

Website:www.pepgen.com/

Clinical Development Pipeline

PGN-EDODM1

Target: DMPK

Myotonic dystrophy type 1

Preclinical

Phase 1

Phase 2

Phase 3

Approved

EDO discovery programs

Target: Undisclosed

Additional neuromuscular and neurological diseases

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

James McArthur

President, Chief Executive Officer & Director

Afsaneh Mohebbi

Senior Vice President, Portfolio & Program

Kasra Kasraian

Chief Technical Officer

Careers & Job Openings

See all open roles at PepGen

All departments

See careers page

Apply Now →